Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- CuraGen Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT00704158
- Locations
- ๐บ๐ธ
Florida Cancer Specialists, Ft. Myers, Florida, United States
๐บ๐ธHematology Oncology Associates, Lake Worth, Florida, United States
๐บ๐ธGeorgia Cancer Specialists, Atlanta, Georgia, United States
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
Phase 1
Completed
- Conditions
- Unresectable Stage III or Stage IV Melanoma
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- CuraGen Corporation
- Target Recruit Count
- 117
- Registration Number
- NCT00412828
- Locations
- ๐บ๐ธ
New York University Medical Center, New York, New York, United States
๐บ๐ธAngeles Clinic and Research Institute, Santa Monica, California, United States
๐บ๐ธM.D. Anderson Cancer Center, Houston, Texas, United States
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- CuraGen Corporation
- Target Recruit Count
- 390
- Registration Number
- NCT00323518
- Locations
- ๐บ๐ธ
Alta Bates Comprehensive Cancer Center, Berkley, California, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธResearch Facility, La Jolla, California, United States
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
Phase 2
Completed
- Conditions
- Stomatitis
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- CuraGen Corporation
- Registration Number
- NCT00104065
- Locations
- ๐บ๐ธ
Research Facility, Portland, Oregon, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath